Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
Overview
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics (NASDAQ:ORKA), reported the direct sale of 9,854 shares of Common Stock for proceeds of approximately $687K across June 12 and June 15, 2026, according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($69.72); post-transaction value based on June 15, 2026 market close.
Details
* 1-year performance calculated using June 15th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.